Signing the binational agreement between NIDA and Institut National de la Santé et de la Recherche Médicale (Inserm) are, from left, NIDA Director Nora D. Volkow, M.D.; His Excellency François Delattre, Ambassador of France; and Inserm Chair and Chief Executive Officer André Syrota, M.D.
As part of the ongoing collaboration under the binational agreement between NIDA and the Italian Department for Antidrug Policies, the NIDA Intramural Research Program (IRP) and researchers at the Catholic University of Rome will conduct joint clinical studies on reducing alcohol consumption. The Italian principal investigator is Giovanni Addolorato, M.D. The research plan was agreed upon during meetings that were held November 6–14, 2012, in Rome and Verona, where NIDA Director Nora D.
Building on the 2011 binational agreement between NIDA and the Italian Department for Anti-Drug Policies (DAP), Italy has translated the NIDA website, Easy-to-Read Drug Facts, into Italian. The easy-to-read website features pictures and videos to help readers understand the text about drug abuse, addiction, and treatment. The pages are easy to print out to share with people who do not have computers.
Building on the 2011 Binational Agreement between NIDA and the Italian Department for Anti-Drug Policies (DAP), NIDA staff and grantees taught a module of the National School on Addiction, which was held March 12–13, 2012, in Italy.
Continuing the uniquely successful binational agreement between NIDA and the Netherlands, three new research teams have received funding to conduct studies on prevention and treatment interventions. NIDA funds the U.S. researchers; the Netherlands Organisation for Health Research and Development (ZonMw) supports the Dutch scientists. The newly funded teams are:
As part of the ongoing binational collaboration on drug abuse research between NIDA and the Spanish Plan Nacional sobre Drogas (PNSD), Spanish researchers may apply for funding from PNSD to support brief research visits with NIDA-funded investigators in the United States.